GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming sales figures in ...

Live news: Airbus sticks with delivery target of ‘around’ 770 commercial jets in 2024 on facebook (opens in a new window) ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...

Starting November 4, doses of the RSV immunization will also be available for infants and high-risk children up to 24 months ...